* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Presentation - University of Warwick
X-inactivation wikipedia , lookup
Gene therapy wikipedia , lookup
Gene desert wikipedia , lookup
Designer baby wikipedia , lookup
Protein moonlighting wikipedia , lookup
Messenger RNA wikipedia , lookup
Point mutation wikipedia , lookup
Microevolution wikipedia , lookup
Epigenetics of neurodegenerative diseases wikipedia , lookup
Site-specific recombinase technology wikipedia , lookup
Vectors in gene therapy wikipedia , lookup
Gene therapy of the human retina wikipedia , lookup
Deoxyribozyme wikipedia , lookup
Gene expression programming wikipedia , lookup
Epigenetics of diabetes Type 2 wikipedia , lookup
Short interspersed nuclear elements (SINEs) wikipedia , lookup
Long non-coding RNA wikipedia , lookup
Polyadenylation wikipedia , lookup
Gene nomenclature wikipedia , lookup
RNA interference wikipedia , lookup
Nutriepigenomics wikipedia , lookup
Artificial gene synthesis wikipedia , lookup
Epigenetics of human development wikipedia , lookup
Nucleic acid tertiary structure wikipedia , lookup
Polycomb Group Proteins and Cancer wikipedia , lookup
Gene expression profiling wikipedia , lookup
History of RNA biology wikipedia , lookup
Primary transcript wikipedia , lookup
RNA silencing wikipedia , lookup
Therapeutic gene modulation wikipedia , lookup
Mir-92 microRNA precursor family wikipedia , lookup
Epitranscriptome wikipedia , lookup
RNA-binding protein wikipedia , lookup
c-Myc regulated functional gene and protein networks involved in tumourigenesis Sam Robson Bsc Msc Biomedical Research Institute, University of Warwick, CV4 7AL Supervised by Michael Kahn, David Epstein and Stella Pelengaris 1: The c-Myc Oncogene 3: Pancreatic cancer Deregulation of the c-Myc (Carcinoma Myelocytomatosis) proto-oncogene is seen in many human cancers. The protein product is a transcription factor that works in a heterodimeric complex with the protein Max (figure 1). This complex controls cell cycle progression (G1 to S phase), inhibits terminal differentiation, and (somewhat paradoxically) can induce apoptosis. Control of aberrant c-Myc expression has been the goal of several therapeutic techniques (reviewed in Robson et al., 2005). However, the precise genetic pathways involved in c-Myc induced cancer are not yet fully understood. It is hoped that a better understanding can be reached through analysis of changes at the transcriptional level. Legend Myc Box I Myc Box II Basic Amino terminal 1 Helix-Loop-Helix Leucine Zipper Carboxyl terminal 45 63 129 143 355 368 410 Amino acid 439 C-Myc Protein Max Protein Transactivation domain Figure 1: The structure of the c-Myc onco-protein and its dimerization with the protein Max. 2: Transgenic c-Myc Transgenic c-Myc provides a switchable model for Myc induced cancer. The cMyc onco-protein is inactive until application of 4-hydroxytamoxifen, a ligand for the bound estrogen receptor (figure 2). Continued administration of 4-OHT results in a prolonged cancer phenotype. Tumour regression occurs when tamoxifen administration is halted. Legend Myc Box I Myc Box II Basic 1 Helix-Loop-Helix Leucine Zipper Estrogen Receptor 4: Results The pancreas is responsible for regulating blood glucose levels. It contains hundreds of colonies of cells within the exocrine tissue, consisting predominately of β-cells, the main source of insulin within the body. Mouse models have been created with the chimeric c-MycERTAM gene active in the pancreatic β-cells. Activation results in increased β-cell proliferation, but also overwhelming apoptosis, leading to islet involution and death (figure 3). The anti-apoptotic gene BclXL (beta-cell lymphoma extra large) was introduced as a second transgene to suppress apoptosis. Activation of c-MYCERTAM in double transgenic mice results in rapid, synchronous entry of nearly all β-cells into the cell-cycle with no discernable c-Myc induced apoptosis, resulting in grossly hyperplastic islets (figure 3). C-MycERTAM (Apoptosis) INACTIVE ACTIVE +4OHT Pancreatic Islet β-Cells Apoptosis outweighs proliferation Proliferation and Apoptosis C-MycERTAM + BclXL (Apoptosis Blocked) INACTIVE ACTIVE •Hyperplasia •Loss of differentiation •Loss of cell-cell contact •Local invasion •Angiogenesis +4OHT Pancreatic Islet β-Cells Proliferation Insulinoma Figure 3: The effect of activating c-Myc activity is overwhelming apoptosis. A second transgene, BclXL is introduced to block Mycinduced apoptosis, resulting in unchecked proliferative activity. Bound Heat Shock Protein 90 4: Microarray Analysis ERTAM HSP90 Microarrays are high density oligonucleotide chips able to measure the expression levels of every gene within the genome in parallel by measuring mRNA levels. Affymetrix Genechips are commercially available microarrays with very high reproducibility. Total RNA 2 3 cDNA Reverse Transcription AAAA In Vitro Transcription B B AAAA B Myc HSP90 Max 4-OHT binds estrogen receptor opening up bHLHz domain. ERTAM 4 Myc-Max complex binds E-box sequence of target gene Myc AAAA Max binds Myc at leucine helix-loophelix zipper region Fragmentation of cRNA Affymetrix Genechip Microarray ERTAM 5 Max TRRAP Active MycERTAM Myc Myc Max Genechip features contain oligonucleotide 25mers antisense to cRNA strands TransformationTranscription domain Associated Protein (TRRAP) binds to MBII with help from MBI + B B B B B B HAT TRRAP RNA Polymerase B B B B Max B B B B B 18s and 28s peaks different heights C Airdried section Fixed section D 18s and 28s peaks nonexistant 18s and 28s peaks nonexistant E Stained section 18s and 28s peaks nonexistant Figure 6: Reduction in RNA integrity during LCM protocol. A shows the bioanalyser readout for intact RNA. The 28s and 18s ribosomal peaks are prominent and roughly the same size, indicating good RNA quality. B-E shows the reduction in RNA quality as the LCM protocol progresses. Airdrying alone is enough to destroy RNA integrity completely. 5: Conclusions To analyse relevant gene changes within the β-cells, laser capture microscopy was implemented, allowing isolation of pancreatic islets. However, the process is relatively lengthy, involving sectioning, fixing, staining and dehydrating before LCM can be performed. Once LCM has been improved to a degree, work can commence on microarray work to study the changes in gene expression levels during the first few hours of c-Myc activation. B Acknowledgements Analysis of gene expression data in Genespring Import .CEL file into Genespring for analysis CACGTG Figure 2: Activation of the MycERTAM transgene by addition of the ligand 4-Hydroxytamoxifen, and subsequent transcriptional activation following dimerization with the protein Max. Fresh section B Scan chip and convert to .CEL file Scanned microarray image B B B B B B Wash and Stain chip Control sample Work continues on optimizing the LCM procedure, including trying various staining protocols, and using a perfusion technique to allow RNA fixation in vivo before extraction. Biotin-labelled cRNA hybridized to Genechip B B Myc B Hybridization of biotin-labelled cRNA to Microarray CACGTG TRRAP recruits a histone acetyltransferase (HAT). This acetylates nucleosomal histones resulting in chromatin remodelling, allowing access by RNA Polymerase for gene transcription Unfortunately, the LCM protocol allows RNase activity. As the protocol progresses, RNA integrity is reduced (figure 6). By the time islet tissue is collected, RNA is completely degraded (figure 6E). There are various possible methods for preventing RNA degradation during LCM procedure, and these will be used to optimise the technique. During this time, RNA becomes gradually more degraded. By the time LCM can be performed, RNA integrity is too poor to run on a microarray. Several approaches have been attempted so far, including using RNAlater to protect RNA, and DEPCs to prevent RNase activity, but so far have proved fruitless. B Fluorescently labelled hybridized chip CACGTG Fragmented biotinlabelled cRNA strands B Figure 5: Scatter plots for replicate samples. Ideally all points should lie along diagonal. Curved graphs indicate replicates have significant discrepancies. Analysis of the effects of c-Myc at the transcriptional level will provide an insight into the role that the onco-protein plays in the onset of cancer. Understanding the mechanisms by which cancer comes will help to improve therapeutic methods. Microarrays allow parallel analysis of the expression changes of thousands of genes, and so offer a powerful genomics tool. Biotin-labelled cRNA AAAA Unbound Heat Shock Protein 90 Laser capture microscopy (LCM) can be used to isolate islet tissue for microarrays. 18s and 28s peaks similar heights Data is imported into the gene analysis software Genespring, producing a timecourse of gene expression after Myc activation. +4-Hydroxytamoxifen Use of whole pancreas tissue poses a problem for gene expression analysis – the ratio of islet tissue to exocrine tissue is not constant across time points. This means that data is not necessarily comparable across the time-course. A mRNA is extracted from pancreatic tissue at various timepoints from the start of 4-OHT administration, and run on a mouse Affymetrix Genechip (figure 4). Inactive MycERTAM Myc 6 Islet involution Triplicates are run for all time points for statistical significance. Scatter plots of replicates indicates that there are significant discrepancies between replicate samples (figure 5). Curved graphs (notably the time 0 data) indicates dissimilarity in the samples. Figure 4: Gene expression analysis through 1-colour Microarray analysis. Many thanks to Mike, David and Stella for taking me on for this project, and to Vicky Ifandi, Sylvie Abouna, Göran Mattson and Linda Cheung for always being willing to help when I lost my way. Thanks also to Helen Bird, Sue Davis and Lesley for all their work on the microarray side of things. This project is funded by the Engineering and Physical Sciences Research Council, through the MOAC Doctoral Training Centre. Mco A